Báez-de la Fuente E, Arellano-Severiano B

Language: Spanish
References: 21
Page: 330-333
PDF size: 50.13 Kb.

ABSTRACT

Background: Resistance and intolerance to imatinib in patients with chronic myeloid leukemia requires alternative therapies. Nilotinib provides a choice as a second-line treatment. The objective of this report was to show the results of a group of patients with chronic myeloid leukemia who received nilotinib as a second-line treatment.
Methods: The medical records of 16 patients of both sexes, of any age, diagnosed with chronic myeloid leukemia, who received nilotinib as a second-line treatment, were reviewed. All of them had received imatinib prior as fi rst-line treatment; the causes to switch to nilotinib were intolerance, resistance and clinical progression of leukemia.
Results: The sample was of 16 patients, who achieved at least a hematologic response; 10 were males (62.5%). The age range was 24 to 75 years. Two patients received nilotinib due to intolerance to imatinib; seven due to resistance to imatinib and seven due to lack of response. There was response in the two patients who received nilotinib due to intolerance. One patient died fi ve months after starting nilotinib due to progression of leukemia; four patients achieved major molecular response, two patients had reduced expression of BCR-ABL gene. Six patients continued with high expression of BCR-ABL gene; two of them carrying M244V mutation, and one with a complex karyotype with numerical and structural alterations.
Conclusions: Nilotinib is an option for patients with intolerance or resistance to imatinib.

REFERENCES

1. Kantarjian HM, Talpaz M. Defi nition of the accelerated phase of chronic myelogenous leukemia. J Clin Oncol. 1998;6(1):180-2.

2. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood. 2000;96(10):3343-56.

3. Jahagirdar BN, Miller JS, Shet A, Verfaillie CM. Novel therapies for chronic myelogenous leukemia. Exp Hematol. 2001;29(5):543-56.

4. Enright H, McGlave PB. Biology and treatment of chronic myelogenous leukemia. Oncology (Williston Park). 1997;11(9):1295-300.

5. Capdeville R, Buchdunger E, Zimmermann J, Matter A. GLIVEC (STI571, imatinib) a rationally developed, targeted anticancer drug. Nat Rev Drug Discov. 2002;1(7):493-502.

6. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural mechanism for the STI-571 inhibition of abelson tyrosine kinase. Science. 2000;289(5486):1938-42.

7. O´Brien SG, Guihot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytararbine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994-1004.

8. Hui C, Hughes TP. Strategies for the treatment of imatinib-resistant chronic myeloid leukemia. Clin Adv Hematol Oncol. 2003;1(9):538-45, 559.

9. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to STI- 571 cancer therapy caused by BCR/ABL gene mutation or amplifi cation. Science. 2001;293(5531): 876-80.

10. Hochhaus A, Kreil S, Corbin AS, La Rosée P, Müller MC, Lahaye T, Hanfstein B, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia. 2002;16(11):2190-6.

11. Branford S, Rudzki Z, Walsh S, Grigg A, Arthur C, Taylor K, et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood. 2002;99(9):3472-5.

12. Roche-Lestienne C, Soenen-Cornu V, Gradel-Dufl os N, Lai JL, Philippe N, Facon T, et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood. 2002;100(3):1014-8.

13. Roumiantsev S, Shah NP, Gorre ME, Nicoll J, Brasher BB, Sawyers CL, et al. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain Ploop. Proc Natl Acad Sci USA, 2002;99(16):10700-5.

14. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2002;2(2):117-25.

15. Novartis Pharmaceuticals Corporation. (2007). Tasigna ® (nilotinib) [Prescribing information]. East Hanover, NJ: Author.

16. O’Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J, et al. In vitro activity of BCR-ABL inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005;65(11):4500-5.

17. Weisberg E, Manley PW, Breitenstein W, Brüggen J, Cowan-Jacob SW, Ray A, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005;7(2),129-41.

18. Kantarjian HM, Hochhaus A, Cortes, J, Martinelli G, Bhalla KN, Giles FJ, et al. Nilotinib is highly active and safe in chronic phase chronic myelogenous leukemia (CML-CP) patients with imatinib-resistance or intolerance. Blood (ASH Annual Meeting Abstracts). 2007;110:735.

19. le Coutre P, Giles FJ, Apperley J, Ottmann OG, Gattermann N, O’Brien SG, et al. Nilotinib is safe and effective in accelerated phase chronic myelogenous leukemia (CML-AP) patients with imatinib resistance or intolerance. Blood (ASH Annual Meeting Abstracts). 2007;110:471.

20. Kantarjian HM, Giles FJ, Hochhaus A, Bhalla KN, Ossenkoppele GJ, Gattermann N, et al. Nilotinib in patients with imatinib-resistant or -intolerant chronic myelogenous leukemia in chronic phase (CML-CP): Updated phase II results. J Clin Oncol. 2008;26:abstract 7010. Disponible en http://www.asco.org/ ASCOv2/Meetings/Abstracts?

21. Hughes T, Saglio G, Martinelli G, Kim DW, Soverini S, Mueller M, et al. Responses and disease progression in CML-CP patients treated with nilotinib after imatinib failure appear to be affected by the BCRABL mutation status and types. Blood (ASH Annual Meeting Abstracts). 2007;110:320.